by Deborah M. Stephens, and John C. Byrd

Slides:

Advertisements

Similar presentations

Atrial Fibrillation Dr Nidhi Bhargava 8/10/13.

Advertisements

Atrial Fibrillation Current Management Strategies.

Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the.

CHADS 2 -> CHA 2 DS 2 VASc. CHA2DS2-VASc Risk Score CHF or LVEF < 40% 1 Hypertension1 Age > 752 Diabetes1 Stroke/TIA/ Thromboembolism 2 Vascular Disease.

The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. Benefit of Anticoagulation Unlikely in Patients With Atrial.

Date of download: 6/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Urinary Sodium and Potassium Excretion and Risk of.

Estimated 24-h urinary excretion of sodium and composite of cardiovascular death.. Figure 3. Estimated 24-h urinary excretion of sodium and composite of.

Case 66 year old male with PMH of HTN, DM, ESRD on renal replacement TIW, stroke in 2011 with right side residual weakness, atrial fibrillation, currently.

CHA2DS2-VASC and CHADS2 Scores Predict Adverse Clinical Events in Patients With Pacemakers and Sinus Node Dysfunction Independent of Atrial Fibrillation

Copyright © 2011 American Medical Association. All rights reserved.

No evidence that AF type significantly impacts stroke risk

ELIGIBILITY: MRC/BHF Heart Protection Study

Serum Total 25‐OH Vitamin D Adds Little Prognostic Value in Patients Undergoing Coronary Catheterization by Michael E. Gerling, Matthew T. James, Stephen.

Circ Cardiovasc Qual Outcomes

Hazard ratio (HR) for mortality for a 1-kg/m2 increase in body mass index (BMI) across the range of baseline BMI among patients with acute ischemic stroke.

Role of the CHADS2 Score in Acute Coronary Syndromes

CHADS2 Score Predicts Postoperative Atrial Fibrillation in Patients Undergoing Elective Pulmonary Lobectomy Svetlana Kotova, MD, Mansen Wang, PhD, Katie.

Cohort study of preoperative blood pressure and risk of 30-day mortality after elective non-cardiac surgery S. Venkatesan, P.R. Myles, H.J. Manning,

Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control

Mechanisms, Clinical Significance, and Prevention of Cognitive Impairment in Patients With Atrial Fibrillation Lena Rivard, MD, MSc, Paul Khairy, MD,

Chapter 6: CKD among Children and Adolescents

by James O. Armitage, and Dan L. Longo

Rituximab-induced tumor cell agglutination

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib by Preetesh Jain, Michael Keating, William Wierda, Zeev Estrov, Alessandra.

The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naïve.

Volume 83, Issue 3, Pages (March 2013)

Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure Steven Fishbane, Nobuyuki Miyawaki Kidney International

CHA2DS2-VASc Score Is Directly Associated with the Risk of Pulmonary Embolism in Patients with Atrial Fibrillation Walid Saliba, MD, MPH, Gad Rennert,

Step Care Therapy for Hypertension in Diabetic Patients

Practical Guidance on Using New Therapies for Relapsed/ Refractory Follicular Lymphoma and Chronic Lymphocytic Leukemia.

Navigating New Oral Treatment Algorithms in CLL

Managing Adverse Events With New Oral Therapies in CLL

Implementing BCR Signaling Inhibitor Therapy in Relapsed CLL

Long-Term Risk of Ischemic Stroke After the Cox-Maze III Procedure for Atrial Fibrillation Anders Albåge, MD, PhD, Ulrik Sartipy, MD, PhD, Göran Kennebäck,

Optimizing Outcomes and Managing Adverse Events in CLL

Dileep Raman et al. JACEP 2017;3:

Gregory Y.H. Lip, MD, Jonathan L. Halperin, MD, Hung-Fat Tse, MD, PhD

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

CHADS2 Score, Statin Therapy, and Risks of Atrial Fibrillation

Volume 145, Issue 1, Pages (January 2014)

Wesley T. O’Neal et al. JACEP 2016;2:

Are Atrial Fibrillation Patients Receiving Warfarin in Accordance with Stroke Risk? Peter J. Zimetbaum, MD, Amit Thosani, MD, Hsing-Ting Yu, MPH, Yan.

Managing Age-Related Clinical Issues in Hemophilia

Left atrial appendage exclusion: An alternative to anticoagulation in nonvalvular atrial fibrillation Kareem Bedeir, MBChB, MS, David R. Holmes, MD,

Isla M. Ogilvie, PhD, Nick Newton, PhD, Sharon A

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

Molly E. Waring, PhD, Jane S

Guidelines for the Older Adult With CKD

How I treat cancer-associated venous thromboembolism

Optimizing Atrial Fibrillation Management

C.Y. Hsu, J.D. Ordoñez, G.M. Chertow, D. Fan, C.E. McCulloch, A.S. Go

Managing CLL With BTK Inhibitors

Nat. Rev. Cardiol. doi: /nrcardio

Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib by Tracy E. Wiczer, Lauren B. Levine, Jessica.

Stroke and Bleeding Risk Co-distribution in Real-world Patients with Atrial Fibrillation: The Euro Heart Survey Maura Marcucci, MD, Gregory Y.H. Lip,

Volume 87, Issue 1, Pages (January 2015)

Enrollment of patients.

Volume 72, Issue 4, Pages (August 2007)

Adjusted ORs of AF within 30 days after bereavement with specific characteristics versus non-bereaved with the same characteristics. * *The vertical dashed.

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Erratum Canadian Journal of Cardiology

Renovascular operations in patients with chronic renal insufficiency: Do the benefits justify the risks? John W. Hallett, M.D., Richard Fowl, M.D., Peter.

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Adjusted ORs of AF according to time since bereavement versus non-bereaved in a population from Denmark between 1995 and * *ORs are adjusted for.

Adjusted prevalence of CHD, atrial fibrillation, and stroke by sex and ethnic group. Numbers for sex are adjusted for age and clustering within practices.

Risk differences for incident stroke, coronary heart disease (CHD), and cardiovascular mortality (per 1000 person-years) by clinical risk factor in the.

Figure 8. Stroke prevention strategy in patients with AF

Figure 1. Decision-making process of stroke prevention in patients with AF from Asia. The decision-making process includes stroke risk evaluation, OAC.

The CHA(2)DS2-(VASc) stroke risk and HAS-BLED bleeding risk index are calculated by totalling the scores for each risk factor present.68–71 The lower graph.

Presentation transcript:

by Deborah M. Stephens, and John C. Byrd How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia by Deborah M. Stephens, and John C. Byrd Blood Volume 133(12):1298-1307 March 21, 2019 ©2019 by American Society of Hematology

Proposed mechanisms for ibrutinib-related adverse events. Deborah M. Stephens, and John C. Byrd Blood 2019;133:1298-1307 ©2019 by American Society of Hematology

Management of atrial fibrillation in patients treated with ibrutinib Management of atrial fibrillation in patients treated with ibrutinib. *Notable drug interactions with ibrutinib include diltiazem, verapamil, and amiodarone (CYP3A4 inhibitors) and amiodarone (P-glycoprotein). #1 point each for a history of congestive heart... Management of atrial fibrillation in patients treated with ibrutinib. *Notable drug interactions with ibrutinib include diltiazem, verapamil, and amiodarone (CYP3A4 inhibitors) and amiodarone (P-glycoprotein). #1 point each for a history of congestive heart failure, hypertension, diabetes mellitus, or vascular disease, age 65 to 74 years, or female sex and 2 points each for age ≥75 years or a history of stroke. $Discuss risk of thromboembolic events with patient. ^Possible options include venetoclax with or without rituximab, idelalisib, and duvelisib. Deborah M. Stephens, and John C. Byrd Blood 2019;133:1298-1307 ©2019 by American Society of Hematology